Mode
Text Size
Log in / Sign up
N/A Completed N=30 Basic Science

Cimarrón Bean Extrudate Solution on Platelet Function and Biochemical Parameters

Postprandial Glucose · Platelet Activation
Source: ClinicalTrials.gov NCT07043829 ↗
Enrolled (actual)
30
Serious AEs
0.0%
Results posted
Apr 2026
Primary outcomePrimary: Change in Platelet Reactivity After Acute Consumption of SPVCE — 0.23; 0.16; 0.05; 0.05 μM — p=0.02

Summary

This non-randomized acute clinical trial evaluates the effect of consuming a water-based solution of Cimarrón bean extrudate on platelet function and postprandial glycemia in adults. Participants will consume a single 10-gram dose of Cimarrón bean extrudate dissolved in water. Blood samples will be collected before and after the intervention to assess platelet reactivity using flow cytometry and to measure glucose levels through colorimetric spectrophotometry. The total intervention period will last approximately 8 hours. This study aims to explore whether the acute consumption of this legume-based functional product can influence hemostatic and glycemic responses in the postprandial state.

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Platelet Reactivity After Acute Consumption of SPVCE
0.23; 0.16; 0.05; 0.05; 1.96; 1.47 0.02 sig
SECONDARY
Change in Postprandial Blood Glucose Levels After Consumption of SPVCE
87.37; 85.89 0.172
SECONDARY
Change in Postprandial Plasma Concentration of Total Polyphenols After Consumption of SPVCE
624.9; 794.6; 670.5 0.010 sig
SECONDARY
Change in Postprandial Platelet Function (Closure Time) After Consumption of SPVCE
118.9; 113.9 0.320

Eligibility Criteria

Inclusion Criteria

  • Voluntary participant
  • Men and women aged 20-59 years
  • Willingness to participate and provide written informend consent

Exclusion Criteria

  • Documented food allergies, especially ti legumes or beans
  • Diagnosed liver, kidney, , autoinmune diseases or severe illnesses such as cancer.
  • Diagnosed gastrointestinal diseases including inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis), celiac disease, or any condition causing chronic gastrointestinal symptoms such as malabsorption, persistent diarrhea, or gastrointestinal bleeding
  • Use medication known to alter platelet funtion like, antiplatelet agents (aspirin, clopidogrel); Non-steroidal anti-inflamatory drugs (NSAID-Ibuprofen, naproxen); Anticoagulants (Warfarin, heparin, direct oral anticoagulant like rivaroxaban or apixaban); Selective serotonin reuptake inhibitors (SSRIs) and other drugs known to impact platelet aggregation or hemostasis.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT07043829). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search